A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients

H C A Emsley, C J Smith, R F Georgiou, A Vail, S J Hopkins, N J Rothwell, P J Tyrrell, Acute Stroke Investigators, H C A Emsley, C J Smith, R F Georgiou, A Vail, S J Hopkins, N J Rothwell, P J Tyrrell, Acute Stroke Investigators

Abstract

Objectives: The cytokine interleukin (IL)-1 mediates ischaemic brain damage in rodents. The endogenous, highly selective, IL-1 receptor antagonist (IL-1ra) protects against ischaemic cerebral injury in a range of experimental settings, and IL-1ra causes a marked reduction of cell death when administered peripherally or at a delay in transient cerebral ischaemia. We report here the first randomised, double blind, placebo controlled trial of recombinant human IL-1ra (rhIL-1ra) in patients with acute stroke.

Methods: Patients within 6 hours of the onset of symptoms of acute stroke were randomised to rhIL-1ra or matching placebo. Test treatment was administered intravenously by a 100 mg loading dose over 60 seconds, followed by a 2 mg/kg/h infusion over 72 h. Adverse events and serious adverse events were recorded for up to 3 months, serial blood samples were collected for biological markers up to 3 months, and 5-7 day brain infarct volume was measured by computed tomography.

Results: No adverse events were attributed to study treatment among 34 patients randomised. Markers of biological activity, including neutrophil and total white cell counts, C reactive protein, and IL-6 concentrations, were lower in rhIL-1ra treated patients. Among patients with cortical infarcts, clinical outcomes at 3 months in the rhIL-1ra treated group were better than in placebo treated.

Conclusions: These data suggest that rhIL-1ra is safe and well tolerated in acute stroke. In addition, rhIL-1ra exhibited biological activity that is relevant to the pathophysiology and clinical outcome of ischaemic stroke. Our findings identify rhIL-1ra as a potential new therapeutic agent for acute stroke.

References

    1. Stroke. 1999 Nov;30(11):2355-9
    1. Md State Med J. 1965 Feb;14:61-5
    1. Stroke. 2000 Jun;31(6):1223-9
    1. Brain Res. 2000 Jul 14;871(1):57-65
    1. J Cereb Blood Flow Metab. 2000 Sep;20(9):1276-93
    1. J Neurosurg. 2001 Oct;95(4):680-6
    1. J Neurosurg. 2002 Apr;96(4):736-41
    1. Stroke. 2002 Jun;33(6):1545-50
    1. Cytokine Growth Factor Rev. 2002 Aug-Oct;13(4-5):323-40
    1. Brain Behav Immun. 2003 Jun;17(3):152-7
    1. J Neuroimmunol. 2003 Jun;139(1-2):93-101
    1. Br J Pharmacol. 2003 Oct;140(3):471-6
    1. Stroke. 2003 Oct;34(10):2518-32
    1. J Neurol Neurosurg Psychiatry. 2003 Nov;74(11):1476-84
    1. BMC Neurol. 2004 Jan 15;4:2
    1. Cerebrovasc Dis. 2004;18(3):220-6
    1. Acta Neurol Scand. 1985 May;71(5):396-400
    1. Stroke. 1988 May;19(5):604-7
    1. Lancet. 1991 Jun 22;337(8756):1521-6
    1. Crit Care Med. 1994 Jan;22(1):12-21
    1. Stroke. 1994 Nov;25(11):2220-6
    1. J Neuroimmunol. 1994 Dec;55(2):153-60
    1. Exp Neurol. 1994 Dec;130(2):362-7
    1. Brain Res. 1995 Feb 13;671(2):261-6
    1. Ann Neurol. 1995 Jun;37(6):800-5
    1. J Pharm Sci. 1995 May;84(5):575-80
    1. Crit Care Med. 1997 Jul;25(7):1115-24
    1. Drug Saf. 1999 Feb;20(2):109-17
    1. Brain Res. 1999 May 29;830(1):32-7
    1. J Neuroimmunol. 1999 Dec;100(1-2):203-15

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi